Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CHRS · as of Jun 8, 2026
Key Statistics
Explore Coherus Oncology, Inc. Data
chrs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 16 · Buy rate: 81.3%
The CHRS analyst consensus is Buy, based on ratings from 16 Wall Street analysts over the past 3 months. The average 12-month price target is $6.02, representing +313.75% upside from the current price of $1.46.
Competitors & Peers
chrs competitorsCHRS
AVTX
CCCC
CDXS
IMDX
IVVDStock Performance
Full HistoryAbout Coherus Oncology, Inc.
Coherus Oncology, Inc. a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulas…
what is coherus oncology, inc. · chrs stock overview · coherus oncology, inc. company profile · who is coherus oncology, inc. ceo · chrs NASDAQ · coherus oncology, inc. headquarters · coherus oncology, inc. business segments
About Stock Overview & Key Data
Coherus Oncology, Inc. (CHRS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 6, 2014. As of the latest trading session, CHRS stock price is $1.46, with a market capitalization of $176.3M. The stock has returned +68.54% over the past 12 months and +1.41% year-to-date.
According to 16 Wall Street analysts, the consensus rating for Coherus Oncology, Inc. stock is Buy, with an average 12-month price target of $6.02. In fiscal year 2025, Coherus Oncology, Inc. reported revenue of $42.2M and net income of -$170.3M. For detailed data — including Coherus Oncology, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Coherus Oncology, Inc. (CHRS) stock price is $1.46. The stock is traded on NASDAQ under the ticker symbol CHRS. The 52-week range is $0.71 – $2.62.